Dr. Lakshmi N. Rajdev, MD

Dr. Rajdev practices at Mount Sinai West in New York, New York, part of Mount Sinai Health System.

Dr. Rajdev's NPI, 1053491548, was assigned on October 17, 2006. Dr. Rajdev holds New York license 195576.

Dr. Rajdev's primary practice is Mount Sinai West, at 1000 Tenth Avenue, New York, NY 10019 in New York County. The practice phone is (212) 523-4000.

Dr. Rajdev's primary practice is Mount Sinai West in New York, New York, part of Mount Sinai Health System. The medical group on file is Mount Sinai Institute for Liver Medicine.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rajdev practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Rajdev's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Rajdev is licensed in New York.

CMS data shows 140 Medicare services from Dr. Rajdev across 3 procedure codes in 2024, all of them office visits, for 45 Medicare patients. Medicare paid $15,138 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 45 Medicare patients who saw Dr. Rajdev in 2024. The largest group is 65 to 74, with 22 patients. 69% of them have high blood pressure, and 62% have cancer. 40% are also on Medicaid. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rajdev's median patient age at 69, with 44% women.

In 2024, Dr. Rajdev wrote 227 Medicare Part D claims for 39 patients. 91% of them were for generic drugs. CMS names the drug for 141 of them, across 6 drugs with 11 or more claims each, at $1,223 in total drug cost. In 2020, CMS named 55 claims across 3 drugs.

Dr. Rajdev accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rajdev as offering telehealth.

Dmand AI links 34 papers to Dr. Rajdev, published from 2011 to 2025. 2019 was the busiest year, with 4. The most frequent topics are Immunotherapy, Antineoplastic Combined Chemotherapy Protocols and Anus Neoplasms. Dr. Rajdev has published most often in J Clin Oncol. Dr. Rajdev's most frequent co-authors are Jennifer W. Chuy, MD, Santiago Aparo, MD and Imran N. Chaudhary, MD.

Dmand AI links Dr. Rajdev to 7 clinical trials, 4 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Anus Neoplasms, Adenocarcinoma Of Esophagus and Anal Canal Carcinoma. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 172 general payments to Dr. Rajdev from 31 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 70% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $13,432.